Evaluation of Neuropathological Effects of a High-Fat Diet in a Presymptomatic Alzheimer’s Disease Stage in APP/PS1 Mice
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is currently an incurable aging-related neurodegenerative disorder. Recent studies give support to the hypotheses that AD should be considered as a metabolic disease. The present study aimed to explore the relationship between hippocampal neuropathological amyloid-β (Aβ) plaque formation and obesity at an early presymptomatic disease stage (3 months of age). For this purpose, we used APPswe/PS1dE9 (APP/PS1) transgenic mice, fed with a high-fat diet (HFD) in order to investigate the potential molecular mechanisms involved in both disorders. The results showed that the hippocampus from APP/PS1 mice fed with a HFD had an early significant decrease in Aβ signaling pathway specifically in the insulin degrading enzyme protein levels, an enzyme involved in (Aβ) metabolism, and α-secretase. These changes were accompanied by a significant increase in the occurrence of plaques in the hippocampus of these mice. Furthermore, APP/PS1 mice showed a significant hippocampal decrease in PGC-1α levels, a cofactor involved in mitochondrial biogenesis. However, HFD does not provoke changes in neither insulin receptors gene expression nor enzymes involved in the signaling pathway. Moreover, there are no changes in any enzymes (kinases) involved in tau phosphorylation, such as CDK5, and neither in brain oxidative stress production. These results suggest that early changes in brains of APP/PS1 mice fed with a HFD are mediated by an increase in Aβ1 ‒ 42, which induces a decrease in PKA levels and alterations in the p-CREB/ NMDA2B /PGC1-α pathway, favoring early AD neuropathology in mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 2×
“This hypothesis states that depositions of the amyloidpeptide (A ) produce senile plaques, that lead to the formation of neurofibrillary tangles, which in turn cause neuronal death that lead to a cognitive decline [6–10].”
BackgroundThe novel object recognition memory: neurobiology, test procedure, and its modifications
Antunes, M., & Biala, G. (2012) · Cognitive Processing · doi:10.1007/s10339-011-0430-z · Cited by 2,390 · cited 1×
“Exploration was defined as the orientation of snout of the animals toward the object, sniffing or touching [49].”
BackgroundSt-Pierre, J., Drori, S., Uldry, M., Silvaggi, J. M., Rhee, J., Jäger, S., Handschin, C., Zheng, K., Lin, J., Yang, W., et al. (2006) · Cell · doi:10.1016/j.cell.2006.09.024 · Cited by 2,233 · cited 3×
“Previous reported data suggest that PGC-1 expression is decreased in the brain of AD patients and that this decrease could be accompanied by mitochondrial alterations [55–58].”
BackgroundAβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938 · cited 1×
“This hypothesis states that depositions of the amyloidpeptide (A ) produce senile plaques, that lead to the formation of neurofibrillary tangles, which in turn cause neuronal death that lead to a cognitive decline [6–10].”
BackgroundJankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575 · cited 4×
“Furthermore, it has been demonstrated that APP/PS1 mice show early memory loss that becomes evident at the age of 6 months [39–42].”
BackgroundMethodInfluentialAn english translation of alzheimer’s 1907 paper, “über eine eigenartige erkankung der hirnrinde”
Stelzmann, R. A., Norman Schnitzlein, H., & Reed Murtagh, F. (1995) · Clinical Anatomy · doi:10.1002/ca.980080612 · Cited by 1,455
Alzheimer’s disease is type 3 diabetes—Evidence reviewed
de la Monte, S. M., & Wands, J. R. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200619 · Cited by 1,158 · cited 1×
“Thus, some researchers denominate AD as type III diabetes [22].”
BackgroundAβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology
Radde, R., Bolmont, T., Kaeser, S. A., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun, M. E., Jäggi, F., Wolburg, H., Gengler, S., et al. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400784 · Cited by 986 · cited 1×
“In the APP/PS1 line, two strategies are combined to reach elevated A levels: overexpression of the mutant human amyloid precursor protein (APP) encoding gene, together with the mutant presenilin1 (PS1) gene, which additionally impairs amyloid protein processing, leading to elevated A 42 levels [45–47].”
BackgroundSignaling pathways in insulin action: molecular targets of insulin resistance
Pessin, J. E., & Saltiel, A. R. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10582 · Cited by 939
A “mitochondrial cascade hypothesis” for sporadic Alzheimer’s disease
Swerdlow, R. H., & Khan, S. M. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2003.12.045 · Cited by 758 · cited 1×
“Likewise, Swerdlow and Khan, proposed the so-called “mitochondrial cascade” hypothesis, suggesting that mitochondria damage occurs prior to brain A accumulation [14–17].”
Background
Cited by
Lam, V., Takechi, R., Hackett, M. J., Francis, R., Bynevelt, M., Celliers, L. M., Nesbit, M., Mamsa, S., Arfuso, F., Das, S., et al. (2021) · PLOS Biology · doi:10.1371/journal.pbio.3001358 · Cited by 80
“Moreover, synergistic effects of TRL-Aβ with exaggerated central nervous system (CNS) synthesis of human Aβ are also suggested by the findings of accelerated amyloidosis in amyloid precursor protein/presenilin 1 (APP/PS1) mice maintained on atherogenic diets [9].”
BackgroundEttcheto, M., Cano, A., Manzine, P. R., Busquets, O., Verdaguer, E., Castro-Torres, R. D., García, M. L., Beas-Zarate, C., Olloquequi, J., Auladell, C., et al. (2020) · Molecular Neurobiology · doi:10.1007/s12035-019-01849-6 · Cited by 73
Self-citationState of the science on brain insulin resistance and cognitive decline due to Alzheimer's disease
Rhea, E. M., Leclerc, M., Yassine, H. N., Capuano, A. W., Tong, H., Petyuk, V. A., Macauley, S. L., Fioramonti, X., Carmichael, O., Calon, F., et al. (2023) · Aging and disease · doi:10.14336/ad.2023.0814 · Cited by 70
“In addition, 3-month-old HFD-fed APP/PS1 showed no differences in the activation of these kinases in the hippocampus and no change in tau protein phosphorylation of various epitopes [171].”
BackgroundIntegrated approach reveals diet, APOE genotype and sex affect immune response in APP mice
Nam, K. N., Wolfe, C. M., Fitz, N. F., Letronne, F., Castranio, E. L., Mounier, A., Schug, J., Lefterov, I., & Koldamova, R. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.10.018 · Cited by 32
“Third, numerous studies using mouse models of AD reported that in adult mice, HFD aggravates cognitive deficit and AD related pathology, such as amyloid deposition and neuroinflammation [15-21].”
Metadata
- Authors
- Ettcheto, M., Petrov, D., Pedrós, I., Alva, N., Carbonell, T., Beas-Zarate, C., Pallas, M., Auladell, C., Folch, J., & Camins, A.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2016-08-23
- Volume
- 54
- Issue
- 1
- Pages
- 233-251
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2468164711
- Cited by
- 63
- References
- 23
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.